FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297492764> ?p ?o ?g. }

• W4297492764 endingPage "1" @default.
• W4297492764 startingPage "1" @default.
• W4297492764 abstract "Background: Severe COVID-19 course is associated with higher inflammatory state (cytokine storm) due to the excessive release of pro-inflammatory cytokines. Some preliminary results showed higher disease severity as well as mortality in patients with COVID-19 accompanying cancer. In this study, we aimed to evaluate the high dose intravenous anakinra treatment response and outcome in patients with severe and critically ill COVID-19 accompanying cancer. Method: This observational retrospective study was carried out at a tertiary referral center between 01.09.2021 and 01.02.2022 in Turkey. The study population consisted of two groups as follows; the patients receiving high dose intravenous anakinra (anakinra group) and the patients treated with standard of care (SoC, control group). Anakinra was started in patients who did not respond to steroid therapy at least two days or concomitantly with steroids in patients with higher risk and/or critical illness at admission. Results: Data of 146 patients in anakinra and 114 patients in control group were analyzed. Median±interquartile range (IQR) patient age was 71 (25) years, duration of hospitalization were 11 (12) days in anakinra group and 65.5 (23) years and 9 (7.3) days in control group, respectively. Fifty-seven (39 %) and 68 (59.6 %) patients had severe, 89 (61 %) and 46 (40.4 %) had critical disease in anakinra and control group, respectively. Overall, ICU admission was in 58 (39.7 %) and 25 (22 %), intubation was in 52 (35.6 %) and 13 (11.4 %) patients, 54 (37 %) and 27 (23.7 %) patients died in anakinra and control group, respectively. Malignancy frequency was 11 % (n=16) in anakinra group and 7 % (n=8) in the control group. In survival analysis, significantly lower survival rate was observed in patients with malignancy than those without in control group (Log-Rank: p=0.002) and patients with malignancy in control group compared to anakinra group (Log-Rank: p=0.013); but did not differ between patients with and without malignancy in anakinra group (Log-Rank: p=0.9). Conclusion: In our study, mortality was higher in patients with malignancy compared to those without control but not in anakinra group and also higher in patients receiving anakinra compared to SoC. Our study indicates that intravenous high dose anakinra treatment is safe and effective in patients with COVID-19 associated cytokine storm accompanying cancer." @default.
• W4297492764 created "2022-09-29" @default.
• W4297492764 creator A5008448004 @default.
• W4297492764 creator A5027306056 @default.
• W4297492764 creator A5040879853 @default.
• W4297492764 creator A5048975604 @default.
• W4297492764 creator A5054286376 @default.
• W4297492764 creator A5083535779 @default.
• W4297492764 date "2022-09-28" @default.
• W4297492764 modified "2023-09-27" @default.
• W4297492764 title "Individualized High Dose Intravenous Anakinra Treatment is Safe and Effective in Patients with COVID-19 Associated Cytokine Storm Accompanying Cancer: A Retrospective Matched Study" @default.
• W4297492764 doi "https://doi.org/10.31487/j.ijcst.2022.04.03" @default.
• W4297492764 hasPublicationYear "2022" @default.
• W4297492764 type Work @default.
• W4297492764 citedByCount "0" @default.
• W4297492764 crossrefType "journal-article" @default.
• W4297492764 hasAuthorship W4297492764A5008448004 @default.
• W4297492764 hasAuthorship W4297492764A5027306056 @default.
• W4297492764 hasAuthorship W4297492764A5040879853 @default.
• W4297492764 hasAuthorship W4297492764A5048975604 @default.
• W4297492764 hasAuthorship W4297492764A5054286376 @default.
• W4297492764 hasAuthorship W4297492764A5083535779 @default.
• W4297492764 hasConcept C119060515 @default.
• W4297492764 hasConcept C126322002 @default.
• W4297492764 hasConcept C141071460 @default.
• W4297492764 hasConcept C167135981 @default.
• W4297492764 hasConcept C2779134260 @default.
• W4297492764 hasConcept C2779559532 @default.
• W4297492764 hasConcept C2781228260 @default.
• W4297492764 hasConcept C3008058167 @default.
• W4297492764 hasConcept C524204448 @default.
• W4297492764 hasConcept C71924100 @default.
• W4297492764 hasConceptScore W4297492764C119060515 @default.
• W4297492764 hasConceptScore W4297492764C126322002 @default.
• W4297492764 hasConceptScore W4297492764C141071460 @default.
• W4297492764 hasConceptScore W4297492764C167135981 @default.
• W4297492764 hasConceptScore W4297492764C2779134260 @default.
• W4297492764 hasConceptScore W4297492764C2779559532 @default.
• W4297492764 hasConceptScore W4297492764C2781228260 @default.
• W4297492764 hasConceptScore W4297492764C3008058167 @default.
• W4297492764 hasConceptScore W4297492764C524204448 @default.
• W4297492764 hasConceptScore W4297492764C71924100 @default.
• W4297492764 hasLocation W42974927641 @default.
• W4297492764 hasOpenAccess W4297492764 @default.
• W4297492764 hasPrimaryLocation W42974927641 @default.
• W4297492764 hasRelatedWork W2002120878 @default.
• W4297492764 hasRelatedWork W2003938723 @default.
• W4297492764 hasRelatedWork W2047967234 @default.
• W4297492764 hasRelatedWork W2061253854 @default.
• W4297492764 hasRelatedWork W2118496982 @default.
• W4297492764 hasRelatedWork W2439875401 @default.
• W4297492764 hasRelatedWork W3084999278 @default.
• W4297492764 hasRelatedWork W4297492764 @default.
• W4297492764 hasRelatedWork W4306737004 @default.
• W4297492764 hasRelatedWork W3183219692 @default.
• W4297492764 isParatext "false" @default.
• W4297492764 isRetracted "false" @default.
• W4297492764 workType "article" @default.